Neuronetics (NASDAQ:STIM) Releases Earnings Results, Misses Estimates By $0.07 EPS

Neuronetics (NASDAQ:STIM - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.07), Zacks reports. The company had revenue of $22.49 million during the quarter, compared to analyst estimates of $18.98 million. Neuronetics had a negative net margin of 50.09% and a negative return on equity of 141.24%. Neuronetics updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Neuronetics Stock Performance

Shares of STIM traded up $0.11 during mid-day trading on Friday, reaching $5.07. The company's stock had a trading volume of 1,463,479 shares, compared to its average volume of 572,968. The company has a current ratio of 3.16, a quick ratio of 2.87 and a debt-to-equity ratio of 4.90. Neuronetics has a 1-year low of $0.52 and a 1-year high of $5.92. The business has a 50-day simple moving average of $3.13 and a two-hundred day simple moving average of $1.72. The stock has a market cap of $153.86 million, a P/E ratio of -4.12 and a beta of 2.07.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group increased their price target on shares of Neuronetics from $5.00 to $8.00 and gave the company a "buy" rating in a research note on Wednesday.

Insider Buying and Selling

In other news, CEO Keith J. Sullivan sold 40,992 shares of the firm's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $3.28, for a total transaction of $134,453.76. Following the completion of the sale, the chief executive officer now owns 1,283,362 shares in the company, valued at approximately $4,209,427.36. This trade represents a 3.10 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Stephen Furlong sold 17,307 shares of the company's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $4.11, for a total transaction of $71,131.77. Following the completion of the transaction, the chief financial officer now owns 454,420 shares in the company, valued at approximately $1,867,666.20. This trade represents a 3.67 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 100,369 shares of company stock valued at $358,929. 9.80% of the stock is owned by insiders.

Remove Ads

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.